<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>TERCONAZOLE- terconazole cream </strong><br>Taro Pharmaceuticals U.S.A., Inc.<br></p></div>
<h1>Terconazole <br> Vaginal Cream 0.4%</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="DLDE"></a><a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-1"></a><p></p>
<p class="First"><span class="Bold">Rx Only</span></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="section-2"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">Terconazole Vaginal Cream 0.4% is a white to off-white, water washable cream for intravaginal administration containing 0.4% of the antifungal agent terconazole, <span class="Italics">cis</span>-1-[<span class="Italics">p</span>-[[2-(2,4-Dichlorophenyl)-2-(1<span class="Italics">H</span>-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]-4-isopropylpiperazine, compounded in a cream base consisting of butylated hydroxyanisole, cetyl alcohol, isopropyl myristate, polysorbate 60, polysorbate 80, propylene glycol, purified water, and stearyl alcohol.</p>
<p>The structural formula of terconazole is as follows:</p>
<table class="Noautorules" width="80%">
<col align="right" valign="bottom" width="70%">
<col align="left" valign="middle" width="30%">
<tbody class="Headless"><tr>
<td align="right"><img alt="Chemical Structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=2b3923b5-0a97-428c-b8d2-4a3ceb3447a1&amp;name=terconazole-01.jpg"></td>
<td align="left">TERCONAZOLE<br>C<span class="Sub">26</span>H<span class="Sub">31</span>CI<span class="Sub">2</span>N<span class="Sub">5</span>O<span class="Sub">3</span>
</td>
</tr></tbody>
</table>
<p>Terconazole, a triazole derivative, is a white to almost white powder with a molecular weight of 532.47. It is insoluble in water; sparingly soluble in ethanol; and soluble in butanol.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="section-3"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="section-3.1"></a><p></p>
<h2>Absorption</h2>
<p class="First">Following a single intravaginal application of a suppository containing 240 mg <span class="Sup">14</span>C-terconazole to healthy women, approximately 70% (range: 64 to 76%) of terconazole remains in the vaginal area during the suppository retention period (16 hours); approximately 10% (range: 5 to 16%) of the administered radioactivity was absorbed systemically over 7 days. Maximum plasma concentrations of terconazole occur 5 to 10 hours after intravaginal application of the cream or suppository. Systemic exposure to terconazole is approximately proportional to the applied dose, whether as the cream or suppository. The rate and extent of absorption of terconazole are similar in patients with <span class="product-label-link" type="condition" conceptid="198363" conceptname="Candidiasis of vagina">vulvovaginal candidiasis</span> (pregnant or non-pregnant) and healthy subjects.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-3.2"></a><p></p>
<h2>Distribution</h2>
<p class="First">Terconazole is highly protein bound (94.9%) in human plasma and the degree of binding is independent of drug concentration over the range of 0.01 to 5 mcg/mL.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-3.3"></a><p></p>
<h2>Metabolism</h2>
<p class="First">Systemically absorbed terconazole is extensively metabolized (&gt;95%).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-3.4"></a><p></p>
<h2>Elimination</h2>
<p class="First">Across various studies in healthy women, after single or multiple intravaginal administration of terconazole as the cream or suppository/ovule, the mean elimination half-life of unchanged terconazole ranged from 6.4 to 8.5 hours. Following a single intravaginal administration of a suppository containing 240 mg <span class="Sup">14</span>C-terconazole to hysterectomized or tubal ligated women, approximately 3 to 10% (mean ± SD: 5.7 ± 3%) of the administered radioactivity was eliminated in the urine and 2 to 6% (mean ± SD: 4.2 ± 1.6%) was eliminated in the feces during the 7-day collection period.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-3.5"></a><p></p>
<h2>Multiple Dosing</h2>
<p class="First">There is no significant increase in maximum plasma concentration or overall exposure (AUC) after multiple daily applications of the cream for 7 days or suppositories for 3 days.</p>
<p><span class="product-label-link" type="condition" conceptid="4080920" conceptname="Phytophotodermatitis">Photosensitivity reactions</span> were observed in some normal volunteers following repeated dermal application of terconazole 2% and 0.8% creams under conditions of filtered artificial ultraviolet light.</p>
<p><span class="product-label-link" type="condition" conceptid="4080920" conceptname="Phytophotodermatitis">Photosensitivity reactions</span> have not been observed in U.S. and foreign clinical trials in patients who were treated with terconazole suppositories or vaginal cream (0.4% and 0.8%).</p>
</div>
<div class="Section" data-sectionCode="49489-8">
<a name="section-3.6"></a><p></p>
<h2>Microbiology</h2>
<div class="Section" data-sectionCode="43679-0">
<a name="section-3.6.1"></a><p></p>
<h3>Mechanism of action</h3>
<p class="First">Terconazole, an azole antifungal agent, inhibits fungal cytochrome P-450-mediated 14 alpha-lanosterol demethylase enzyme. This enzyme functions to convert lanosterol to ergosterol. The accumulation of 14 alpha-methyl sterols correlates with the subsequent loss of ergosterol in the fungal cell wall and may be responsible for the antifungal activity of terconazole. Mammalian cell demethylation is less sensitive to terconazole inhibition.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-3.6.2"></a><p></p>
<h3>Activity <span class="Italics">in vitro</span>
</h3>
<p class="First">Terconazole exhibits antifungal activity <span class="Italics">in vitro</span> against <span class="Italics"><span class="product-label-link" type="condition" conceptid="433968" conceptname="Candidiasis">Candida</span> albicans</span> and other <span class="Italics"><span class="product-label-link" type="condition" conceptid="433968" conceptname="Candidiasis">Candida</span></span> species. The MIC values of terconazole against most <span class="Italics">Lactobacillus</span> spp. typically found in the human vagina were  ≥ 128 mcg/mL; therefore these beneficial bacteria are not affected by drug treatment.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="section-4"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<p class="First">Terconazole vaginal cream is indicated for the local treatment of <span class="product-label-link" type="condition" conceptid="198363" conceptname="Candidiasis of vagina">vulvovaginal candidiasis</span> (<span class="product-label-link" type="condition" conceptid="433968" conceptname="Candidiasis">moniliasis</span>). As terconazole vaginal cream is effective only for <span class="product-label-link" type="condition" conceptid="4180978" conceptname="Vulvovaginitis">vulvovaginitis</span> caused by the genus <span class="Italics"><span class="product-label-link" type="condition" conceptid="433968" conceptname="Candidiasis">Candida</span></span>, the diagnosis should be confirmed by KOH smears and/or cultures.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="section-5"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First">Patients known to be hypersensitive to terconazole or to any of the components of the cream.</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="section-6"></a><p></p>
<h1>WARNINGS</h1>
<p class="First"><span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">Anaphylaxis</span> and <span class="product-label-link" type="condition" conceptid="443754" conceptname="Lyell's toxic epidermal necrolysis, subepidermal type">toxic epidermal necrolysis</span> have been reported during terconazole therapy. Terconazole therapy should be discontinued if <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span> or <span class="product-label-link" type="condition" conceptid="443754" conceptname="Lyell's toxic epidermal necrolysis, subepidermal type">toxic epidermal necrolysis</span> develops.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="section-7"></a><p></p>
<h1>PRECAUTIONS</h1>
<div class="Section" data-sectionCode="34072-9">
<a name="section-7.1"></a><p></p>
<h2>General</h2>
<p class="First">For vulvovaginal use only. Terconazole is not for ophthalmic or oral use. Discontinue use and do not retreat with terconazole if sensitization, irritation, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">chills</span> or flu-like symptoms are reported during use.</p>
</div>
<div class="Section" data-sectionCode="34075-2">
<a name="section-7.2"></a><p></p>
<h2>Laboratory Tests</h2>
<p class="First">If there is lack of response to terconazole, appropriate microbiologic studies (standard KOH smear and/or cultures) should be repeated to confirm the diagnosis and rule out other pathogens.</p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="section-7.3"></a><p></p>
<h2>Drug Interactions</h2>
<p class="First">The therapeutic effect of terconazole is not affected by oral contraceptive usage.</p>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="section-7.4"></a><p></p>
<h2>Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.4.1"></a><p></p>
<h3>Carcinogenesis</h3>
<p class="First">Studies to determine the carcinogenic potential of terconazole have not been performed.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.4.2"></a><p></p>
<h3>Mutagenicity</h3>
<p class="First">Terconazole was not mutagenic when tested <span class="Italics">in vitro</span> for induction of microbial point mutations (Ames test), or for inducing cellular transformation, or <span class="Italics">in vivo</span> for chromosome breaks (micronucleus test) or dominant lethal mutations in mouse germ cells.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.4.3"></a><p></p>
<h3>Impairment of Fertility</h3>
<p class="First">No impairment of fertility occurred when female rats were administered terconazole orally up to 40 mg/kg/day for a three month period.</p>
</div>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="section-7.5"></a><p></p>
<h2>Pregnancy</h2>
<div class="Section" data-sectionCode="34077-8">
<a name="section-7.5.1"></a><p></p>
<h3>Teratogenic Effects</h3>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.5.1.1"></a><p></p>
<h4>Pregnancy Category C</h4>
<p class="First">There was no evidence of <span class="product-label-link" type="condition" conceptid="4240324" conceptname="Teratogenesis">teratogenicity</span> when terconazole was administered orally up to 40 mg/kg/day (100× the recommended intravaginal human dose of the 0.4% vaginal cream formulation) in rats, or 20 mg/kg/day in rabbits, or subcutaneously up to 20 mg/kg/day in rats.</p>
<p>Dosages at or below 10 mg/kg/day produced no embryotoxicity; however, there was a delay in fetal ossification at 10 mg/kg/day in rats. There was some evidence of embryotoxicity in rabbits and rats at 20 to 40 mg/kg. In rats, this was reflected as a decrease in litter size and number of viable young and reduced fetal weight. There was also delay in ossification and an increased incidence of skeletal variants.</p>
<p>The no-effect dose of 10 mg/kg/day resulted in a mean peak plasma level of terconazole in pregnant rats of 0.176 mcg/mL which exceeds by 44 times the mean peak plasma level (0.004 mcg/mL) seen in normal subjects after intravaginal administration of terconazole 0.4% vaginal cream. This safety assessment does not account for possible exposure of the fetus through direct transfer to terconazole from the irritated vagina by diffusion across amniotic membranes.</p>
<p>Since terconazole is absorbed from the human vagina, it should not be used in the first trimester of pregnancy unless the physician considers it essential to the welfare of the patient.</p>
<p>Terconazole may be used during the second and third trimester if the potential benefit outweighs the possible risks to the fetus.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="section-7.6"></a><p></p>
<h2>Nursing Mothers</h2>
<p class="First">It is not known whether this drug is excreted in human milk. Animal studies have shown that rat offspring exposed via the milk of treated (40 mg/kg/orally) dams showed decreased survival during the first few post-partum days, but overall pup weight and <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span> were comparable to or greater than controls throughout lactation. Because many drugs are excreted in human milk, and because of the potential for adverse reaction in nursing infants from terconazole, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="section-7.7"></a><p></p>
<h2>Pediatric Use</h2>
<p class="First">Safety and efficacy in children have not been established.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="section-7.8"></a><p></p>
<h2>Geriatric Use</h2>
<p class="First">Clinical studies of terconazole did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="section-8"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.1"></a><p></p>
<h2>Adverse Reactions from Clinical Trials</h2>
<p class="First">Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.</p>
<p>During controlled clinical studies conducted in the United States, 521 patients with <span class="product-label-link" type="condition" conceptid="198363" conceptname="Candidiasis of vagina">vulvovaginal candidiasis</span> were treated with terconazole 0.4% vaginal cream. Based on comparative analyses with placebo, the adverse experiences considered most likely related to terconazole 0.4% vaginal cream were <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> (26% vs. 17% with placebo) and body <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> (2.1% vs. 0% with placebo). <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Fever</span> (1.7% vs. 0.5% with placebo) and <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">chills</span> (0.4% vs, 0% with placebo), vulvovaginal burning, <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span> and irritation have also been reported. The adverse drug experience on terconazole most frequently causing discontinuation was vulvovaginal <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.2"></a><p></p>
<h2>Post-marketing Experience</h2>
<p class="First">The following adverse drug reactions have been first identified during post-marketing experience with terconazole:. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.</p>
<p>General: <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">Asthenia</span>, <span class="product-label-link" type="condition" conceptid="4266367" conceptname="Influenza">Influenza</span>-Like Illness consisting of multiple listed reactions including <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> and <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">chills</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">myalgia</span>, <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">arthralgia</span>, <span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">malaise</span></p>
<p>Immune: <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span>, <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">Anaphylaxis</span>, Face <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">Edema</span></p>
<p>Nervous: <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span></p>
<p>Respiratory: <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">Bronchospasm</span></p>
<p>Skin: <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span>, <span class="product-label-link" type="condition" conceptid="443754" conceptname="Lyell's toxic epidermal necrolysis, subepidermal type">Toxic Epidermal Necrolysis</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">Urticaria</span></p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="section-9"></a><p></p>
<h1>OVERDOSAGE</h1>
<p class="First">In the rat, the oral LD<span class="Sub">50</span> values were found to be 1741 and 849 mg/kg for the male and female, respectively. The oral LD<span class="Sub">50</span> values for the male and female dog were ≅1280 and ≥640 mg/kg, respectively.</p>
<p>In the event of oral ingestion of suppository or cream, supportive and symptomatic measures should be carried out. If the cream is accidentally applied to the eyes, wash with clean water or saline and seek medical attention if symptoms persist.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="section-10"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<p class="First">One full applicator (5 g) of terconazole vaginal cream (20 mg terconazole) should be administered intravaginally once daily at bedtime for seven consecutive days.</p>
<p>Before prescribing another course of therapy, the diagnosis should be reconfirmed by smears and/or cultures and other pathogens commonly associated with <span class="product-label-link" type="condition" conceptid="4180978" conceptname="Vulvovaginitis">vulvovaginitis</span> ruled out. The therapeutic effect of terconazole vaginal cream is not affected by menstruation.</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="section-11"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First">Terconazole Vaginal Cream 0.4% is available in 45 g (NDC 51672-1304-6) tubes with a measured-dose applicator.</p>
<div class="Section" data-sectionCode="44425-7">
<a name="section-11.1"></a><p></p>
<p class="First"><span class="Bold">Store at 20°-25°C (68°-77°F)</span> [see USP Controlled Room Temperature].</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-12"></a><p></p>
<p class="First">Mfd. by: Taro Pharmaceuticals Inc., Brampton, Ontario, Canada L6T 1C1<br>Dist. by: <span class="Bold">Taro Pharmaceuticals U.S.A., Inc.,</span> Hawthorne, NY 10532<br>Revised: August, 2014</p>
<p>PK-3491-2 72</p>
</div>
<div class="Section" data-sectionCode="42230-3">
<a name="section-13"></a><p></p>
<h1>Terconazole<br>Vaginal Cream 0.4%</h1>
<p class="First"><span class="Bold">PATIENT INSTRUCTIONS</span></p>
<p><span class="Bold">FILLING THE APPLICATOR:</span></p>
<p><span class="Bold">1.</span> Remove the cap from the tube.</p>
<p><img alt="Figure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=2b3923b5-0a97-428c-b8d2-4a3ceb3447a1&amp;name=terconazole-02.jpg"></p>
<p><span class="Bold">2.</span> Use the pointed tip on the top of the cap to puncture the seal on the tube.</p>
<p><img alt="Figure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=2b3923b5-0a97-428c-b8d2-4a3ceb3447a1&amp;name=terconazole-03.jpg"></p>
<p><span class="Bold">3.</span> Screw the applicator onto the tube.</p>
<p><span class="Bold">4.</span> Squeeze the tube from the bottom and fill the applicator until the plunger stops.</p>
<p><span class="Bold">5.</span> Unscrew the applicator from the tube.</p>
<div class="Figure"><img alt="Figure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=2b3923b5-0a97-428c-b8d2-4a3ceb3447a1&amp;name=terconazole-04.jpg"></div>
<p><span class="Bold">USING THE APPLICATOR:</span></p>
<p><span class="Bold">1.</span> Lie on your back with your knees drawn up toward your chest.</p>
<p><span class="Bold">2.</span> Holding the applicator by the ribbed end of the barrel, insert the filled applicator into the vagina <span class="Underline">as far as it will comfortably go.</span></p>
<p><span class="Bold">3.</span> Slowly press the plunger of the applicator to release the cream into the vagina.</p>
<p><img alt="Figure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=2b3923b5-0a97-428c-b8d2-4a3ceb3447a1&amp;name=terconazole-05.jpg"></p>
<p><span class="Bold">4.</span> Remove the applicator from the vagina.</p>
<p><span class="Bold">5.</span> Apply one applicatorful each night for as many days at bedtime, as directed by your doctor.</p>
<p><span class="Bold">CLEANING THE APPLICATOR:</span></p>
<p>After each use, you should thoroughly clean the applicator by following the procedure below:</p>
<p><span class="Bold">1.</span> Pull the plunger out of the barrel.</p>
<p><img alt="Figure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=2b3923b5-0a97-428c-b8d2-4a3ceb3447a1&amp;name=terconazole-06.jpg"></p>
<p><span class="Bold">2.</span> Wash the pieces with lukewarm, soapy water, and dry them thoroughly.</p>
<p><span class="Bold">3.</span> Put the applicator back together by gently pushing the plunger into the barrel as far as it will go.</p>
<p>NOTE: Store at 20°-25°C (68°-77°F) [see USP Controlled Room Temperature]. See end flap of carton or crimp of tube for lot number and expiration date.</p>
<p><span class="Bold">A WORD ABOUT <span class="product-label-link" type="condition" conceptid="432248" conceptname="Opportunistic mycosis">YEAST INFECTIONS</span></span></p>
<p><span class="Bold">Why do <span class="product-label-link" type="condition" conceptid="432248" conceptname="Opportunistic mycosis">yeast infections</span> occur?</span></p>
<p><span class="product-label-link" type="condition" conceptid="432248" conceptname="Opportunistic mycosis">Yeast infections</span> are caused by an organism called<span class="Italics"> <span class="product-label-link" type="condition" conceptid="433968" conceptname="Candidiasis">Candida</span> </span>(KAN di duh). It may be present in small and harmless amounts in the mouth, digestive tract, and vagina. Sometimes the natural balance of the vagina becomes upset. This may lead to rapid growth of<span class="Italics"> <span class="product-label-link" type="condition" conceptid="433968" conceptname="Candidiasis">Candida</span>, </span>which results in a <span class="product-label-link" type="condition" conceptid="432248" conceptname="Opportunistic mycosis">yeast infection</span>. Symptoms of a <span class="product-label-link" type="condition" conceptid="432248" conceptname="Opportunistic mycosis">yeast infection</span> include <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span>, burning, <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">redness</span>, and an abnormal discharge.</p>
<p>Your doctor can make the diagnosis of a <span class="product-label-link" type="condition" conceptid="432248" conceptname="Opportunistic mycosis">yeast infection</span> by evaluating your symptoms and looking at a sample of the discharge under the microscope.</p>
<p><span class="Bold">How can I prevent <span class="product-label-link" type="condition" conceptid="432248" conceptname="Opportunistic mycosis">yeast infections</span>?</span></p>
<p>Certain factors may increase your chance of developing a <span class="product-label-link" type="condition" conceptid="432248" conceptname="Opportunistic mycosis">yeast infection</span>. These factors don't actually cause the problem, but they may create a situation that allows the yeast to grow rapidly.</p>
<ul class="Disc">
<li>
<span class="Bold">Clothing: </span>Tight jeans, nylon underwear, pantyhose, and wet bathing suits can hold in heat and moisture (two conditions in which yeast organisms thrive). Looser pants or skirts, 100% cotton underwear, and stockings may help avoid this problem.</li>
<li>
<span class="Bold">Diet: </span>Cutting down on sweets, milk products, and artificial sweeteners may reduce the risk of <span class="product-label-link" type="condition" conceptid="432248" conceptname="Opportunistic mycosis">yeast infections</span>.</li>
<li>
<span class="Bold">Antibiotics: </span>Antibiotics work by eliminating disease-causing organisms. While they are helpful in curing other problems, antibiotics may lead to an overgrowth of<span class="Italics"> <span class="product-label-link" type="condition" conceptid="433968" conceptname="Candidiasis">Candida</span> </span>in the vagina.</li>
<li>
<span class="Bold">Pregnancy: </span>Hormonal changes in the body during pregnancy encourage the growth of yeast. This is a very common time for an <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> to occur. Until the baby is born, it may be hard to completely eliminate <span class="product-label-link" type="condition" conceptid="432248" conceptname="Opportunistic mycosis">yeast infections</span>. If you believe you are pregnant, tell your doctor.</li>
<li>
<span class="Bold">Menstruation: </span>Sometimes monthly changes in hormone levels may lead to <span class="product-label-link" type="condition" conceptid="432248" conceptname="Opportunistic mycosis">yeast infections</span>.</li>
<li>
<span class="Bold"><span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">Diabetes</span>: </span>In addition to heat and moisture, yeast thrives on sugar. Because diabetics often have sugar in their urine, their vaginas are rich in this substance. Careful control of <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> may help prevent <span class="product-label-link" type="condition" conceptid="432248" conceptname="Opportunistic mycosis">yeast infection</span>.</li>
</ul>
<p>Controlling these factors can help eliminate <span class="product-label-link" type="condition" conceptid="432248" conceptname="Opportunistic mycosis">yeast infections</span> and may prevent them from coming back.</p>
<p><span class="Bold">Some other helpful tips:</span></p>
<p><span class="Bold">1. </span>For best results, be sure to use the medication as prescribed by your doctor, even if you feel better quickly.</p>
<p><span class="Bold">2.</span> Avoid sexual intercourse, if your doctor advises you to do so.</p>
<p><span class="Bold">3.</span> If your partner has any penile <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span>, <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">redness</span>, or <span class="product-label-link" type="condition" conceptid="4090431" conceptname="Discomfort">discomfort</span>, he should consult his physician and mention that you are being treated for a <span class="product-label-link" type="condition" conceptid="432248" conceptname="Opportunistic mycosis">yeast infection</span>.</p>
<p><span class="Bold">4.</span> You can use the medication even if you are having your menstrual period. However, you should not use tampons because they may absorb the medication. Instead, use external pads or napkins until you have finished your medication. You may also wish to wear a sanitary napkin if the vaginal medication leaks.</p>
<p><span class="Bold">5.</span> Dry the genital area thoroughly after showering, bathing, or swimming. Change out of a wet bathing suit or damp exercise clothes as soon as possible. A dry environment is less likely to encourage the growth of yeast.</p>
<p><span class="Bold">6.</span> Wipe from front to rear (away from the vagina) after a bowel movement.</p>
<p><span class="Bold">7.</span> Don't douche unless your doctor specifically tells you to do so. Douching may disturb the vaginal balance.</p>
<p><span class="Bold">8.</span> Don't scratch if you can help it. Scratching can cause more irritation and spread the <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>.</p>
<p><span class="Bold">9.</span> Discuss with your physician any medication you are already taking. Certain types of medication can make your vagina more susceptible to <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>.</p>
<p><span class="Bold">10.</span> Eat nutritious meals to promote your general health.</p>
<p>Mfd. by:<br>Taro Pharmaceuticals Inc.<br>Brampton, Ontario, Canada L6T 1C1</p>
<p>Dist. by:<br><span class="Bold">Taro Pharmaceuticals U.S.A., Inc.</span><br>Hawthorne, NY 10532</p>
<p>Revised: August, 2014<br>PK-3491-2 72</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-14"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL - 45 g Tube Carton</h1>
<p class="First"><span class="Bold">NDC 51672-1304-6</span></p>
<p><span class="Bold">Terconazole<br>Vaginal<br>Cream 0.4%</span></p>
<p>TUBE AND APPLICATOR<br>FOR VAGINAL USE ONLY.</p>
<p><span class="Bold">Keep this and all medications out of the reach of children.</span></p>
<p><span class="Bold">45 g</span></p>
<p><span class="Bold">Rx only</span></p>
<p><span class="Bold">TARO</span></p>
<div class="Figure"><img alt="Principal Display Panel - 45 g Tube Carton" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=2b3923b5-0a97-428c-b8d2-4a3ceb3447a1&amp;name=terconazole-07.jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>TERCONAZOLE 		
					</strong><br><span class="contentTableReg">terconazole cream</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:51672-1304</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">VAGINAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>Terconazole</strong> (Terconazole) </td>
<td class="formItem">Terconazole</td>
<td class="formItem">4 mg  in 1 g</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>butylated hydroxyanisole</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>cetyl alcohol</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>isopropyl myristate</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>polysorbate 60</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>polysorbate 80</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>propylene glycol</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>stearyl alcohol</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>water</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">WHITE (white to off-white) </td>
<td class="formLabel">Score</td>
<td class="formItem">    </td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem"></td>
<td class="formLabel">Size</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:51672-1304-6</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">45 g in 1 TUBE, WITH APPLICATOR; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA076043</td>
<td class="formItem">01/19/2005</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Taro Pharmaceuticals U.S.A., Inc.
							(145186370)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Taro Pharmaceuticals Inc.</td>
<td class="formItem"></td>
<td class="formItem">206263295</td>
<td class="formItem">MANUFACTURE(51672-1304)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 9/2014<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>9e19014b-b467-4045-88dd-96134272fa02</div>
<div>Set id: 2b3923b5-0a97-428c-b8d2-4a3ceb3447a1</div>
<div>Version: 4</div>
<div>Effective Time: 20140903</div>
</div>
</div> <div class="DistributorName">Taro Pharmaceuticals U.S.A., Inc.</div></p>
</body></html>
